Moderna, Inc. (MRNA)
| Market Cap | 12.57B |
| Revenue (ttm) | 2.23B |
| Net Income (ttm) | -3.12B |
| Shares Out | 390.73M |
| EPS (ttm) | -8.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,029,855 |
| Open | 31.33 |
| Previous Close | 30.86 |
| Day's Range | 31.27 - 32.53 |
| 52-Week Range | 22.28 - 48.92 |
| Beta | 1.17 |
| Analysts | Hold |
| Price Target | 33.25 (+3.36%) |
| Earnings Date | Feb 13, 2026 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $33.25, which is an increase of 3.36% from the latest price.
News
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda...
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition
Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental bird flu vaccine, the U.S. drugmaker said on Thursday.
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threa...
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p...
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the...
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership
A major vaccine producer came under pressure following a report federal health regulators plan to tighten vaccine approval rules. Meanwhile, an agreement with the world's most valuable company bolster...
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More
Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back. The S&P 500 and Nasdaq slid about 0.2%, while the Dow dropped 0.4%.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Moderna, Inc. (MRNA) Analyst/Investor Day Transcript
Moderna, Inc. ( MRNA) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Stéphane Bancel - CEO & Director Stephen Hoge - President Jerh Collins - Chief Technical Operations & Qua...
Moderna takes $1.5 billion loan, expects 10% revenue growth next year
Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.
Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash b...
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
Moderna to complete US mRNA manufacturing network with $140 million investment
Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.
Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities
New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturi...
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annu...
What Is Going On With Moderna Stock?
Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over th...
Moderna, Inc. (MRNA) Q3 2025 Earnings Call Transcript
Moderna, Inc. ( MRNA) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Ch...
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago.
Moderna trims top end of full-year forecast on weak COVID vaccine sales
Moderna lowered the top end of its 2025 revenue forecast by $200 million on Thursday, citing weaker-than-expected sales of its COVID-19 vaccine in the U.S. as Americans struggled to access the shots.
Moderna Swings to a Loss on Fewer Covid-19 Vaccine Sales
Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 - $2.0 billion Improves 2025 expected GAAP operating...
Moderna Stock Is Sliding Monday: What's Going On?
Moderna Inc (NASDAQ:MRNA) stock is trading sharply lower on Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.